20 results on '"Esseltine, D.-L."'
Search Results
2. Phase I/II Trial of Lenalidomide, Bortezomib, Doxil, and Dexamethasone in Front-Line Multiple Myeloma: A268
3. Lenalidomide, Bortezomib, and Dexamethasone Has Notable Activity in High-Risk First-Line Myeloma: A224
4. Superior Survival with VMP Versus MP After Longer Follow-up and Response to Subsequent Therapy in VISTA: A232
5. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
6. Fewer bone disease events, improvement in bone remodeling, and evidence of bone healing with bortezomib plus melphalan-prednisone vs. Melphalan-prednisone in the phase III VISTA trial in multiple myeloma
7. Risk factors for, and reversibility of, peripheral neuropathy associated with bortezomib-melphalan-prednisone in newly diagnosed patients with multiple myeloma: Subanalysis of the phase 3 VISTA study
8. Efficacy and Safety of Bortezomib-rituximab (vcr) Vs Rituximab (r) In Patients (pts) With Relapsed, R-naive/-sensitive Follicular Lymphoma (fl): Outcome According To Prior Therapy
9. Matched-pairs analysis of outcomes with bortezomib, melphalan, and prednisone (VMP) treatment for previously untreated multiple myeloma (MM) using long-term follow-up data from the phase 3 VISTA and PETHEMA/GEM05 trials
10. Subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma: subanalysis of patients with renal impairment in the phase III MMY-3021 study
11. Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: Analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone
12. Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy
13. Superior Survival with VMP Versus MP After Longer Follow-up and Response to Subsequent Therapy in VISTA
14. Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy
15. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma
16. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression
17. Response to bortezomib (BOR) and bone metabolism in multiple myeloma patients
18. Retinoblastoma: the case for radiotherapy and for adjuvant chemotherapy.
19. Osteogenic sarcoma following treatment with megavoltage radiation and chemotherapy for bone tumors in children.
20. c-MYC expression and maturity phenotypes are associated with outcome benefit from addition of ixazomib to lenalidomide-dexamethasone in myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.